92 related articles for article (PubMed ID: 36529792)
21. Assessment of pharmacogenomic agreement.
Safikhani Z; El-Hachem N; Quevedo R; Smirnov P; Goldenberg A; Juul Birkbak N; Mason C; Hatzis C; Shi L; Aerts HJ; Quackenbush J; Haibe-Kains B
F1000Res; 2016; 5():825. PubMed ID: 27408686
[TBL] [Abstract][Full Text] [Related]
22. Predicting drug response through tumor deconvolution by cancer cell lines.
Hsu YC; Chiu YC; Lu TP; Hsiao TH; Chen Y
Patterns (N Y); 2024 Apr; 5(4):100949. PubMed ID: 38645769
[TBL] [Abstract][Full Text] [Related]
23. Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel.
Li SC; Stucky A; Chen X; Kabeer MH; Loudon WG; Plant AS; Torno L; Nangia CS; Cai J; Zhang G; Zhong JF
Oncotarget; 2018 Sep; 9(70):33290-33301. PubMed ID: 30279960
[TBL] [Abstract][Full Text] [Related]
24. Improving the power of drug toxicity measurements by quantitative nuclei imaging.
Mikheeva AM; Bogomolov MA; Gasca VA; Sementsov MV; Spirin PV; Prassolov VS; Lebedev TD
Cell Death Discov; 2024 Apr; 10(1):181. PubMed ID: 38637526
[TBL] [Abstract][Full Text] [Related]
25. A random-periods model for expression of cell-cycle genes.
Liu D; Umbach DM; Peddada SD; Li L; Crockett PW; Weinberg CR
Proc Natl Acad Sci U S A; 2004 May; 101(19):7240-5. PubMed ID: 15123814
[TBL] [Abstract][Full Text] [Related]
26. HybriSeq: Probe-based Device-free Single-cell RNA Profiling.
Foyt D; Brown D; Zhou S; Huang B
bioRxiv; 2023 Sep; ():. PubMed ID: 37808850
[TBL] [Abstract][Full Text] [Related]
27. Time-dependent proteomics and drug response in expanding cancer cells.
Pan Y; Xuan Y; Hao P; Chen X; Yan R; Zhang C; Ke X; Qu Y; Zhang X
Pharmacol Res; 2024 Jun; 204():107208. PubMed ID: 38729587
[TBL] [Abstract][Full Text] [Related]
28. Learning chemical sensitivity reveals mechanisms of cellular response.
Connell W; Garcia K; Goodarzi H; Keiser MJ
bioRxiv; 2023 Aug; ():. PubMed ID: 37693536
[TBL] [Abstract][Full Text] [Related]
29. Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling.
Li C; Qiu S; Liu X; Guo F; Zhai J; Li Z; Deng L; Ge L; Qian H; Yang L; Xu B
Signal Transduct Target Ther; 2023 Jun; 8(1):247. PubMed ID: 37369642
[TBL] [Abstract][Full Text] [Related]
30. PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer.
Guo F; Ma J; Li C; Liu S; Wu W; Li C; Wang J; Wang J; Li Z; Zhai J; Sun F; Zhou Y; Guo C; Qian H; Xu B
Cell Death Dis; 2023 Apr; 14(4):272. PubMed ID: 37072408
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.
Tuo Z; Lin Y; Zhang Y; Gao L; Yu D; Wang J; Sun C; Sun X; Wang J; Prasad A; Bheesham N; Meng M; Lv Z; Chen X
Discov Oncol; 2024 May; 15(1):160. PubMed ID: 38735911
[TBL] [Abstract][Full Text] [Related]
32. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects.
Hu Q; Wang M; Wang J; Tao Y; Niu T
Oncol Res; 2024; 32(4):753-768. PubMed ID: 38560563
[TBL] [Abstract][Full Text] [Related]
33. High TPX2 expression results in poor prognosis, and Sp1 mediates the coupling of the CX3CR1/CXCL10 chemokine pathway to the PI3K/Akt pathway through targeted inhibition of TPX2 in endometrial cancer.
Yang M; Mao X; Li L; Yang J; Xing H; Jiang C
Cancer Med; 2024 Mar; 13(5):e6958. PubMed ID: 38466034
[TBL] [Abstract][Full Text] [Related]
34. Reactive Amine Functionalized Microelectrode Arrays Provide Short-Term Benefit but Long-Term Detriment to
Sturgill BS; Hernandez-Reynoso AG; Druschel LN; Smith TJ; Boucher PE; Hoeferlin GF; Thai TTD; Jiang MS; Hess JL; Alam NN; Menendez DM; Duncan JL; Cogan SF; Pancrazio JJ; Capadona JR
ACS Appl Bio Mater; 2024 Feb; 7(2):1052-1063. PubMed ID: 38290529
[TBL] [Abstract][Full Text] [Related]
35. Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K/Akt/mTOR pathway in clear cell renal cell carcinoma.
Gao M; Tuo Z; Jiang Z; Chen Z; Wang J
Heliyon; 2024 Jan; 10(1):e23522. PubMed ID: 38173514
[TBL] [Abstract][Full Text] [Related]
36. PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.
Song F; Wang CG; Mao JZ; Wang TL; Liang XL; Hu CW; Zhang Y; Han L; Chen Z
Front Immunol; 2023; 14():1197152. PubMed ID: 37398672
[TBL] [Abstract][Full Text] [Related]
37. Expression dynamics of periodic transcripts during cancer cell cycle progression and their correlation with anticancer drug sensitivity.
Li CX; Wang JS; Wang WN; Xu DK; Zhou YT; Sun FZ; Li YQ; Guo FZ; Ma JL; Zhang XY; Chang MJ; Xu BH; Ma F; Qian HL
Mil Med Res; 2022 Dec; 9(1):71. PubMed ID: 36529792
[TBL] [Abstract][Full Text] [Related]
38. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide analysis of alternative transcripts in human breast cancer.
Wen J; Toomer KH; Chen Z; Cai X
Breast Cancer Res Treat; 2015 Jun; 151(2):295-307. PubMed ID: 25913416
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
